Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (Biosimilar Collaborations Ireland Ltd.), 地舒单抗生物类似药(Biosimilar Collaborations Ireland Ltd.) |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glucocorticoid-induced osteoporosis | NDA/BLA | Canada | 01 Oct 2024 |